Evidence map›Paper›PMID 42558640›Full record

ArticleFrontiers in immunology2026

Type 1 diabetes is associated with higher plasma levels of biomarkers of neurodegeneration and neuroinflammation.

Meghan E Pauley, Christina Coughlan, Fran Dong, Brian Bucca, Bailey Tanner, Catherine Chartier-Logan, Allison L B Shapiro, Janet K Snell-Bergeon

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Meghan E PauleyBarbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Christina CoughlanUniversity of Colorado Alzheimer's and Cognition Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Fran DongBarbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Brian BuccaBarbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Bailey TannerBarbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Catherine Chartier-LoganBarbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Allison L B ShapiroLifecourse Epidemiology of Adiposity and Diabetes Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Janet K Snell-BergeonBarbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)K12DK133995 · NIDDK · STANFORD UNIVERSITY · PI LINDA A DIMEGLIO, David Matthew Maahs · 2022 to 2026
$16.0M
University of Colorado Anschutz Medical Campus DRCP30DK116073 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JANE E REUSCH · 2020 to 2026
$10.8M
SUBCLINICAL HEART DISEASE IN INSULIN-DEPENDENT DIABETESR01HL061753 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 1999 to 2007
$5.2M
Training Program in Diabetes ResearchT32DK063687 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Andrea Steck · 2002 to 2026
$5.2M
Complications and Comorbidities of Type 1 DiabetesR01HL113029 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SNELL-BERGEON, JANET KATHLEEN · 2013 to 2016
$2.9M
Determinants of Accelerated CVD in Type 1 DiabetesR01HL079611 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 2004 to 2007
$2.3M
NCATS NIH HHS UL1 TR002535NHLBI NIH HHS R01 HL061753NHLBI NIH HHS R01 HL079611NHLBI NIH HHS R01 HL113029NIDDK NIH HHS K12 DK133995NIDDK NIH HHS P30 DK116073NIDDK NIH HHS T32 DK063687
6 · The paper itself

Abstract

Introduction: Type 1 diabetes (T1D) is associated with increased risk of dementias and other neurodegenerative diseases. Plasma biomarkers of neurodegeneration and neuroinflammation hold utility in risk prediction and diagnosis of neurodegenerative disease and other neuropathology, but there remains a paucity of data in the T1D population. This study quantified plasma levels of biomarkers of neurodegeneration and neuroinflammation [phosphorylated tau-181 (pTau-181), total tau (Tau), amyloid beta 42/amyloid beta 40 (Aβ42/40), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL)], and tested associations with T1D and related characteristics. Methods: This cross-sectional analysis of a subset of participants from the Coronary Artery Calcification in Type 1 Diabetes study included adults with and without T1D. Biomarker levels were quantified using Quanterix Simoa, then log-transformed and analyzed using linear regression models adjusted for age, body mass index (BMI), race and ethnicity, smoking status, and estimated glomerular filtration rate (eGFR). A subsequent sensitivity analysis included diabetic retinopathy (DR). Results: 136 adults with T1D (n=90, age 52 years, 58% female, average HbA1c 7.7%) and without T1D (n=46, age 53 years, 57% female, average HbA1c 5.4%) were included. In fully adjusted models, T1D was associated with higher pTau-181 [estimate (pg/mL) 1.221, (95% confidence interval 1.003, 1.486) p=0.046], GFAP [1.296 (1.129, 1.489), p<0.001], and NfL [1.355 (1.162, 1.579), p<0.001], relative to adults without T1D. In the sensitivity analysis, relative to adults without T1D, T1D with moderate/severe DR was associated with higher pTau-181 [1.330 (1.063, 1.663), p=0.013], GFAP [1.369 (1.653, 1.608), p<0.001], and NfL [1.495 (1.252, 1.786), p<0.001], and T1D with none/mild DR was associated with higher GFAP [1.228 (1.046, 1.442), p=0.013] and NfL [1.235 (1.037, 1.470), p=0.018]. As compared to T1D with none/mild DR, T1D with moderate/severe DR was associated with higher NfL [1.211 (1.011, 1.451), p=0.038]. Across both models, eGFR was inversely associated with pTau-181, NfL, and Tau (p<0.05 for all). Discussion: T1D is associated with a greater burden of plasma biomarkers of neurodegeneration and neuroinflammation, and microvascular complications such as DR and impaired kidney function may contribute to this burden. Further study is needed to fully characterize the interplay between these biomarkers and neuropathology in T1D.

Indexed as

BiomarkersDiabetes Mellitus, Type 1Neurodegenerative DiseasesNeuroinflammatory DiseasesAdultAmyloid beta-PeptidesCross-Sectional StudiesFemaleGlial Fibrillary Acidic ProteinHumansMaleMiddle AgedNeurofilament Proteinstau ProteinsAmyloid beta-PeptidesBiomarkersGlial Fibrillary Acidic ProteinNeurofilament Proteinstau ProteinsGFAP – glial fibrillary acidic proteinneurodegenerationneurofilament light chain (NFL)neuroinflammationphosphorylated tau (pTau)plasma biomarkerspTau-181type 1 diabetes

Identifiers

PMID42558640
PMCPMC13437782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.